

Benitec Biopharma

Silence could be golden

Benitec Biopharma has a gene-silencing technology, known as ddRNAi, which offers advantages over competing silencing techniques. The pipeline consists of six in-house. The proposed raise of A\$31.5m would mean the company is funded beyond the completion of a key Phase I/IIa trial (due to start in 2014) for its lead project, TT-034 for Hepatitis C.

Gene silencing offers tantalising potential

Benitec Biopharma has a proprietary transformational gene-silencing technology, DNA-directed RNA interference (ddRNAi), which could provide "one-shot" cures for a number of chronic and life-threatening conditions. Although gene silencing has been beset with problems, the field has recently demonstrated clinical efficacy. ddRNAi appears to offer distinct advantages over other techniques such as siRNA, antisense and zinc finger nucleases. The approach is particularly suited to chronic viral infections, such as Hepatitis B and C, and ocular indications.

Promising early stage development pipeline

Benitec Biopharma has six in-house programmes underway and expects the first, TT-034 for Hepatitis C, to enter clinical trials in Q1 2014. TT-034 uses a well-proven adeno-associated virus (AAV) vector to deliver a ddRNAi construct that targets three diverse parts of the Hepatitis C virus in a single intravenous dose. The FDA cleared TT-034 (Jan14) to start studies at Duke Medical and University of California San Diego in patients who have failed current treatments for hepatitis C.

Out-licensed programmes also progressing

Benitec Biopharma has also licenced ddRNAi to other companies for programmes in HIV/AIDS, retinitis pigmentosa, Huntington's Disease, and cancer vaccines. The most advanced is Calimmune, which is in Phase I/IIa trials with its innovative Cal-1 HIV/AIDS ddRNAi construct and could generate preliminary data during this year.

Valuation: Now a high-risk/high-return proposition

A raise of up to A\$31.5m is underway, which should be sufficient to fund significant progress toward the objective of moving Benitec Biopharma from a preclinical to clinical-stage company. Positive efficacy results from the TT-034 Phase I/IIa clinical study, and to a lesser degree Calimmune's Cal-1 programme, would help validate the ddRNAi platform and should be a major value inflexion point. Nonetheless, while the rewards may be high, the risks remain commensurately high.

Historic financials						
Year end	Revenue (A\$m)	PBT (A\$m)	EPS (A\$)	DPS (A\$)	P/E (x)	Yield (%)
06/12	0.32	(4.11)	(0.11)	0.0	N/A	N/A
06/13	0.52	(3.49)	(0.08)	0.0	N/A	N/A
06/14e	N/A	N/A	N/A	N/A	N/A	N/A
06/15e	N/A	N/A	N/A	N/A	N/A	N/A
Source: Blo	omberg					


Healthcare

Price A\$0.99*
Market cap A\$84m

*As at 19 February 2014

Net cash (A\$) as at 30 September 11.5m 2013

Share price graph



Share details

Code	BLT
Listing	ASX
Shares in issue	85.2m

Business description

Benitec Biopharma has a transformational technology, deoxyribonucleic acid (DNA)-directed ribonucleic acid (RNA) interference (ddRNAi). The therapeutic programmes in development include Hepatitis B & C, lung cancer, AMD and oculopharyngeal muscular dystrophy (OPMD).

Bull

- Potent and effective gene-silencing technique.
- Broad applicability across therapeutic areas.
- Potential to alter disease treatments materially.

Bear

- Technology risk is still relatively high.
- High-profile collaborations required as validation.
- Pipeline is still at early development stages.

Analysts

Franc Gregori +44 (0)20 3077 5728

Dr Mick Cooper +44 (0)20 3077 5734

Dr Philippa Gardener +44 (0)20 3681 2521

healthcare@edisongroup.com



Edison, the investment intelligence firm, is the future of investor interaction with corporates. Our team of over 100 analysts and investment professionals work with leading companies, fund managers and investment banks worldwide to support their capital markets activity. We provide services to more than 400 retained corporate and investor clients from our offices in London, New York, Frankfurt, Sydney and Wellington. Edison is authorised and regulated by the Financial Conduct Authority (https://www.fsa.gov.uk/register/firm/BasicDetails.do/sid=181584). Edison Investment Research (NZ) Limited (Edison NZ) is the New Zealand subsidiary of Edison. NZ is registered on the New Zealand Financial Services only. Edison Investment Research Investment Research Investment Research Investment Research Limited (Edison Aus) [4608589] is the Australian subsidiary of Edison and is not regulated by the Australian Securities and Investment Commission. Edison Germany is a branch entity of Edison Investment Research Limited [4794244]. www.edisongroup.com

Copyright 2014 Edison Investment Research Limited. All rights reserved. This report has been prepared and issued by Edison for publication globally. All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report. Opinions contained in this report represent those of the research department of Edison at the time of publication. The securities described in the Investment Research may not be eligible drien and any access to it, is intended only for "wholesale clients" within the meaning of the Australian Corporations Act. The Investment Research is distributed in the United States by Edison US to major US institutional investors only. Edison US is fis not registered as an investment adviser with the Securities and Exchange Commission. Edison US relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. As such, Edison does not offer or provide personalised advice. We publish information about companies in which we believe our readers may be interested and this information reflects our sincere opinions. The information that we provide or that is derived from our website is not intended to be, and should not be construed by any subscriber or prospective subscriber as Edison's solicitation to effect, or attempt to effect, any transaction in a security. The research in this document is intended for New Zealand residnent professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are "wholesale clients" for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. Edison has a restrictive